new glp 1 drugs in development GLP-1 Market Size to Hit USD 132.79 Bn by 2035 GLP Agonist Clinical Trial Pipeline

Jan Jezek, Chief Scientific Officer at Arecor Therapeutics Computational and AI tools can help model those interactions, but in the end, its down to real-life biology within clinical trials

Statistical analysis Events of reported pancreatitis and exposure (patient years) to either incretin-based drugs (GLP-1 receptor agonists or DPP-4 inhibitors) or non-incretin-based comparator drugs/placebo were compared using contingency table analysis, calculating the ORs, 95% CIs and p values for the comparison, using GraphPad Prism version 5.02 for Windows (GraphPad Software, San Diego, CA, USA

To address this growing global challenge, the World Health Organization (WHO) has developed a guideline on the use of glucagon-like peptide-1 (GLP-1) based therapies, including GLP-1 receptor agonists and GLP-1/GIP dual agonists, for adults living with obesity

One medication that works this way is Tirzepatide, which targets both hormone pathways

Overall it certainly seems to me as if the demonstrated long-term health benefits of GLP-1 drugs amply justify free prescriptions to a significantly larger patient population than is currently the case

Results: A total of eight eligible articles were included, pooling data retrieved from 1895 patients with type 2 diabetes mellitus